Regeneron Pharmaceuticals Inc.’s filing revealed that its EVP Commercial McCourt Marion unloaded Company’s shares for reported $0.77 million on Feb 07. In the deal valued at $769.04 per share,1,000 shares were sold. As a result of this transaction, McCourt Marion now holds 22,079 shares worth roughly $ 16.73 million.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Then, YANCOPOULOS GEORGE sold 13,189 shares, generating $10,552,255 in total proceeds. Upon selling the shares at $800.08, the President and Chief Scientific now owns 200,504 shares.
Before that, GOLDSTEIN JOSEPH L sold 3,613 shares. Regeneron Pharmaceuticals Inc. shares valued at $2,890,400 were divested by the Director at a price of $800.00 per share. As a result of the transaction, GOLDSTEIN JOSEPH L now holds 6,247 shares, worth roughly $4.73 million.
Cowen upgraded its Regeneron Pharmaceuticals Inc. [REGN] rating to an Outperform from a a Market perform in a research note published on Monday, January 30, 2023; the price target was increased to $875 from $775. PT values the company’s stock at a premium of 13.4 to its Monday closing price. A number of analysts have revised their coverage, including JP Morgan’s analysts, who increased its forecast for the stock in mid January from “a Neutral” to “an Overweight”. Raymond James also remained covering REGN and has decreased its forecast on October 26, 2022 with a “an Underperform” recommendation from previously “Mkt perform” rating. Evercore ISI revised its rating on October 17, 2022. It rated REGN as “an In-line” which previously was an “an Outperform”.
Price Performance Review of REGN
On Monday, Regeneron Pharmaceuticals Inc. [NASDAQ:REGN] saw its stock jump 0.11% to $757.79. On the same session, the stock had its day’s lowest price of $756.97, but rose to a high of $771.65. Over the last five days, the stock has gained 1.21%. Regeneron Pharmaceuticals Inc. shares have risen nearly 5.03% since the year began. Nevertheless, the stocks have risen 24.27% over the past one year. While a 52-week high of $800.48 was reached on 02/06/23, a 52-week low of $538.01 was recorded on 01/09/23. SMA at 50 days reached $736.91, while 200 days put it at $683.28. A total of 0.56 million shares were traded, compared to the trading of 0.53 million shares in the previous session.
Levels Of Support And Resistance For REGN Stock
The 24-hour chart illustrates a support level at 752.62, which if violated will result in even more drops to 747.46. On the upside, there is a resistance level at 767.30. A further resistance level may holdings at 776.82. The Relative Strength Index (RSI) on the 14-day chart is 54.38, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 4.81, which suggests price will go up in the next trading period. Percent R suggests that price movement has been low at 45.30%. Stochastics %K at 43.05% indicates the stock is a holding.
How much short interest is there in Regeneron Pharmaceuticals Inc.?
A steep rise in short interest was recorded in Regeneron Pharmaceuticals Inc. stocks on Jan 12, 2023, dropping by 30000.0 shares to a total of 1.41 million shares. Yahoo Finance data shows the prior-month short interest on Dec 14, 2022 was 1.44 million shares. There was a decline of -2.13%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 1.37% of the overall stock float, the days-to-cover ratio (short ratio) fell to 2.21.
Regeneron Pharmaceuticals Inc. [REGN] – Who Are The Largest Shareholders?
In filings from Fidelity Management & Research Co, it is revealed that the company now owns 10,255,901 shares, or roughly 9.58% of the outstanding REGN shares. In other words, the investor’s shares have risen by 266,343 from its previous 13-F filing of 9989558.0. Additionally, The Vanguard Group, Inc. increased 0.85% of its stake after which the total value it holdings stand at $6,283,213,264, while Capital Research & Management Co added 0.27% of its stake to hold $4.73 billion in the firm. Over the last quarter, BlackRock Fund Advisors sold -234,688 shares of Regeneron Pharmaceuticals Inc., while SSgA Funds Management, Inc. sold -90,874 shares. At present, JPMorgan Investment Management, I is holding 4,723,613 shares valued at $3.58 billion. Wellington Management Co. LLP owned 2,416,247 shares of the company at the time of its most recent 13F filing, worth $1.83 billion.
According to FactSet, Regeneron Pharmaceuticals Inc.’s share price will average $842.29 in the next year, based on opinions of analysts polled by the firm. This is up nearly 13.08 percent from its previous closing price of $756.99. Analysts expect Regeneron Pharmaceuticals Inc. stock to reach the higher price of $1011.00, while the lowest price estimate is $605.00. However, 26 analysts have rated REGN stock as an Overweight in their predictions for 2023.